Loading…
Reported covered position: Staff Director, Senate Veterans Affairs Committee; Legislative Director, Senator Bob Graham.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages; Issues related to H.Con.Res. 14.
Mikaela Naylon Give Kids a Chance Act
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act.
Issues related to the orphan drug tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
| PHLOW CORPORATION |
| 16 |
| 2021–2025 |
| SIEMENS HEALTHINEERS | 16 | 2021–2025 |
| Alnylam Pharmaceuticals, Inc. | 10 | 2023–2025 |
| BRISTOL MYERS SQUIBB | 10 | 2021–2023 |
| GILEAD SCIENCES, INC. | 10 | 2023–2025 |
| LEGACY COMMUNITY HEALTH SERVICES | 10 | 2021–2023 |
| ASTELLAS PHARMA US, INC. | 9 | 2023–2025 |
| DELFI DIAGNOSTICS | 9 | 2022–2024 |
| PREVENT OPIOID ABUSE | 9 | 2021–2023 |
| EVERGLADES PROTECTION ALLIANCE, INC. | 8 | 2021–2022 |
| CORMEDIX, INC. | 6 | 2023–2024 |
| DAIICHI SANKYO INC | 6 | 2024–2025 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 4 | 2021 |
| MYRIAD GENETICS INC | 4 | 2024–2025 |
| TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF ELI LILLY AND COMPANY | 4 | 2021 |
| CORTEXYME, INC. | 3 | 2021 |
| MCDERMOTT WILL & EMERY LLP (OBO ALNYLAM PHARMACEUTICALS) | 3 | 2022–2023 |
| AMGEN, INC. | 1 | 2023 |
| MORPHOSYS US INC. | 1 | 2021 |
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to home infusion under Medicare FFS; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
ORPHAN Cures Act
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946 - ORPHAN Cures Act.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946 - ORPHAN Cures Act.
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946 - ORPHAN Cures Act.
Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act.
American Relief Act, 2025
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages; Issues relating to H.R.10545 - American Relief Act, 2025 (PL 118-158).
Give Kids a Chance Act of 2024
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives, H.R.7384/S.4583 - Creating Hope Reauthorization Act of 2024, and H.R.3433 - Give Kids a Chance Act of 2024.
Give Kids a Chance Act of 2024
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives; H.R. 7384/S. 4583 - Creating Hope Reauthorization Act of 2024; H.R. 3433 - Give Kids a Chance Act of 2024; American Relief Act of 2025 (PL 118-158).
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to home infusion under Medicare FFS; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Creating Hope Reauthorization Act of 2024
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives; H.R. 7384/S. 4583 - Creating Hope Reauthorization Act of 2024; H.R. 3433 - Give Kids a Chance Act of 2024; American Relief Act of 2025 (PL 118-158).
Creating Hope Reauthorization Act of 2024
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues impacting rare disease treatments, including rare disease research incentives and the Creating Hope Reauthorization Act of 2024, H.R. 7384.
Creating Hope Reauthorization Act of 2024
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives, H.R.7384/S.4583 - Creating Hope Reauthorization Act of 2024, and H.R.3433 - Give Kids a Chance Act of 2024.
Creating Hope Reauthorization Act of 2024
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues impacting rare disease treatments, including rare disease research incentives and the Creating Hope Reauthorization Act of 2024, H.R. 7384; 2. 4583 - A bill to amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases.
Creating Hope Reauthorization Act of 2024
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives; H.R. 7384/S. 4583 - Creating Hope Reauthorization Act of 2024; H.R. 3433 - Give Kids a Chance Act of 2024; American Relief Act of 2025 (PL 118-158).
Creating Hope Reauthorization Act of 2024
Client: ACADIA PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues impacting rare disease treatments, including rare disease research incentives, H.R.7384/S.4583 - Creating Hope Reauthorization Act of 2024, and H.R.3433 - Give Kids a Chance Act of 2024.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to home infusion under Medicare FFS; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Lower Costs, More Transparency Act
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 5378 - Lower Costs, More Transparency Act; S.2333 - Pandemics and All-hazards Preparedness and Response Act (PAHPARA); Issues related to drug shortages.
Lower Costs, More Transparency Act
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 5378 - Lower Costs, More Transparency Act; S.2333 - Pandemics and All-hazards Preparedness and Response Act (PAHPARA); Issues related to drug shortages.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 8487/S. 3018 - Improving Seniors' Timely Access to Care Act; H.R. 830/S. 1375 - Help Ensure Lower Patient Copays Act.
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 8487/S. 3018 - Improving Seniors' Timely Access to Care Act; H.R. 830/S. 1375 - Help Ensure Lower Patient Copays Act.
Pandemic and All-Hazards Preparedness and Response Act
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 5378 - Lower Costs, More Transparency Act; S.2333 - Pandemics and All-hazards Preparedness and Response Act (PAHPARA); Issues related to drug shortages.
Pandemic and All-Hazards Preparedness and Response Act
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 5378 - Lower Costs, More Transparency Act; S.2333 - Pandemics and All-hazards Preparedness and Response Act (PAHPARA); Issues related to drug shortages.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; S.476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: ALNYLAM PHARMACEUTICALS, INC. · Firm: TIBER CREEK GROUP
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; S.476 - Maintaining Investments in New Innovation Act.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
Improving Seniors’ Timely Access to Care Act of 2022
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 8487/S. 3018 - Improving Seniors' Timely Access to Care Act; H.R. 830/S. 1375 - Help Ensure Lower Patient Copays Act.
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
Improving Seniors’ Timely Access to Care Act of 2021
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 8487/S. 3018 - Improving Seniors' Timely Access to Care Act; H.R. 830/S. 1375 - Help Ensure Lower Patient Copays Act.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Opioid Patients’ Right to Know Act of 2021
Client: PREVENT OPIOID ABUSE · Firm: TIBER CREEK GROUP
Issues related to opioid abuse prevention, H.R. 1185 - Opioid Patients Right to Know Act of 2021.
Inflation Reduction Act of 2022
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to H.R. 5376 - Build Back Better Act; Issues related to FDA user fee agreements, Consolidated Appropriations Act, 2022 (PL 117-103).
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act; Issues related to the American Families Plan; S. Con Res 14; Issues related to women's health.
Inflation Reduction Act of 2022
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing). H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
Inflation Reduction Act of 2022
Client: LEGACY COMMUNITY HEALTH SERVICES · Firm: TIBER CREEK GROUP
American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; H.R. 5376 - Build Back Better Act.
Inflation Reduction Act of 2022
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
H.R. 5376 - Build Back Better Act, Subtitle J (Part D drug pricing).
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization.
H.R. 5376 - Build Back Better, Subtitle J; Inflation Reduction Act of 2022 (PL 117-169), Subtitle B - Prescription Drug Pricing Reform; Issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Inflation Reduction Act of 2022
Client: LEGACY COMMUNITY HEALTH SERVICES · Firm: TIBER CREEK GROUP
American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; H.R. 5376 - Build Back Better Act.
Inflation Reduction Act of 2022
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
H.R. 5376 as renamed - Inflation Reduction Act - Subtitle B; Part D drug pricing.
Inflation Reduction Act of 2022
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization.
Inflation Reduction Act of 2022
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
Inflation Reduction Act of 2022
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials.
Inflation Reduction Act of 2022
Client: LEGACY COMMUNITY HEALTH SERVICES · Firm: TIBER CREEK GROUP
American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; H.R. 5376 - Build Back Better Act.
Inflation Reduction Act of 2022
Client: LEGACY COMMUNITY HEALTH SERVICES · Firm: TIBER CREEK GROUP
American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; H.R. 5376 - Build Back Better Act.
Inflation Reduction Act of 2022
Client: LEGACY COMMUNITY HEALTH SERVICES · Firm: TIBER CREEK GROUP
American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; H.R. 5376 - Build Back Better Act.
Inflation Reduction Act of 2022
Client: LEGACY COMMUNITY HEALTH SERVICES · Firm: TIBER CREEK GROUP
American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; H.R. 5376 - Build Back Better Act.
Inflation Reduction Act of 2022
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to H.R. 5376 - Build Back Better Act; Issues related to FDA user fee agreements (H.R.7667 and S.4348), Consolidated Appropriations Act, 2022 (PL 117-103).
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: TAKEDA PHARMACEUTICALS AMERICA, INC. · Firm: TIBER CREEK GROUP
H.R. 5376 - Build Back Better Act, Subtitle J (Part D drug pricing).
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act; Issues related to the American Families Plan; S. Con Res 14; Issues related to women's health; H.R. 8295 - Appropriations for the Department of Labor, Health and Human Services, and Education, and related agencies for FY 2023; Issues related to Prescription Drug User Fee Reauthorization; H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization.
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act; Issues related to the American Families Plan; S. Con Res 14; Issues related to women's health; H.R. 8295 - Appropriations for the Department of Labor, Health and Human Services, and Education, and related agencies for FY 2023.
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Inflation Reduction Act of 2022
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing). H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
Inflation Reduction Act of 2022
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to H.R. 5376 - Build Back Better Act; H.R. 7667/S. 4348 - Food and Drug Amendments of 2022, Issues related to FDA user fee agreements; Consolidated Appropriations Act, 2022 (PL 117-103); Inflation Reduction Act of 2022 (PL 117-169); The legislative vehicle for the Continuing Resolution (PL 117-180).
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169; Issues related to Prescription Drug User Fee Reauthorization; H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: SIEMENS HEALTHINEERS · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: BRISTOL MYERS SQUIBB · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169; Issues related to Prescription Drug User Fee Reauthorization; H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: ORGANON, LLC · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act; Issues related to the American Families Plan; S. Con Res 14; Issues related to women's health; H.R. 8295 - Appropriations for the Department of Labor, Health and Human Services, and Education, and related agencies for FY 2023; Issues related to Prescription Drug User Fee Reauthorization; H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
Clarifying Remanufacturing to Protect Patient Safety Act of 2022
Client: SIEMENS HEALTHINEERS · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; Issues related to FDA and Medicare reimbursement, Consolidated Appropriations Act, 2023 (PL 117-328); Issues related to cancer care.
Clarifying Remanufacturing to Protect Patient Safety Act of 2022
Client: SIEMENS HEALTHINEERS · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.
Clarifying Remanufacturing to Protect Patient Safety Act of 2022
Client: SIEMENS HEALTHINEERS · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022.
Clarifying Remanufacturing to Protect Patient Safety Act of 2022
Client: SIEMENS HEALTHINEERS · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell).
Food and Drug Amendments of 2022
Client: BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) · Firm: TIBER CREEK GROUP
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); Issues related to Prescription Drug User Fee Reauthorization; Issues related to clinical trials. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
Food and Drug Amendments of 2022
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to H.R. 5376 - Build Back Better Act; H.R. 7667/S. 4348 - Food and Drug Amendments of 2022, Issues related to FDA user fee agreements; Consolidated Appropriations Act, 2022 (PL 117-103); Inflation Reduction Act of 2022 (PL 117-169); The legislative vehicle for the Continuing Resolution (PL 117-180).
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing); H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169; Issues related to Prescription Drug User Fee Reauthorization; H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.
Issues related to drug pricing and reimbursement for prescription drugs related to H.R. 5376 - Build Back Better Act; Issues related to the American Families Plan; S. Con Res 14; Issues related to women's health; H.R. 8295 - Appropriations for the Department of Labor, Health and Human Services, and Education, and related agencies for FY 2023; Issues related to Prescription Drug User Fee Reauthorization; H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell); H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R.5376 - Inflation Reduction Act of 2022 - Public Law No: 117-169.
Food and Drug Amendments of 2022
Client: ASSOCIATION FOR CLINICAL ONCOLOGY · Firm: TIBER CREEK GROUP
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to H.R. 5376 - Build Back Better Act; Issues related to FDA user fee agreements (H.R.7667 and S.4348), Consolidated Appropriations Act, 2022 (PL 117-103).
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell).
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946 - ORPHAN Cures Act.
Issues related to drug pricing and reimbursement for prescription drugs related to the Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to oncology; Issues related to ophthalmology.
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates; Issues related to H.R. 946 - ORPHAN Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to home infusion under Medicare FFS; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to domestic pharmaceutical production.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to laboratory services covered under Medicare.
Filing targets: SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2025 · first_quarter · Q1
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages; Issues related to H.Con.Res. 14.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to drug pricing; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV; Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing). Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328). Issues related to the implementation of the American Relief Act of 2025 (PL 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to IP protections under Bayh/Dole; Issues related to oncology; Issues related to ophthalmology.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to laboratory services covered under Medicare.
Filing targets: SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages; Issues relating to H.R.10545 - American Relief Act, 2025 (PL 118-158).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues impacting rare disease treatments, including rare disease research incentives; H.R. 7384/S. 4583 - Creating Hope Reauthorization Act of 2024; H.R. 3433 - Give Kids a Chance Act of 2024; American Relief Act of 2025 (PL 118-158).
Issues related to the orphan drug tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to home infusion under Medicare FFS; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328).
Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to IP protections under Bayh/Dole; Issues related to oncology; Issues related to ophthalmology.
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues impacting rare disease treatments, including rare disease research incentives, H.R.7384/S.4583 - Creating Hope Reauthorization Act of 2024, and H.R.3433 - Give Kids a Chance Act of 2024.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues relating to Domestic API production.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to laboratory services covered under Medicare.
Filing targets: SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; issues related to drug pricing.
Issues related to FY2024 appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). Issues related to the 340b program - Public Health Service Act (PL 78-410).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2024 · third_quarter · Q3
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via TIBER CREEK GROUP
2024 · third_quarter · RR
Issues related to Medicare and devices.
Issues related to Medicare and devices.
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to FY2024 appropriations.
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; issues related to drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328).
Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues relating to Domestic API production.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORMEDIX, INC. via TIBER CREEK GROUP
2024 · second_quarter · 2T
Issues related to infectious disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues impacting rare disease treatments, including rare disease research incentives and the Creating Hope Reauthorization Act of 2024, H.R. 7384; 2. 4583 - A bill to amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to IP protections under Bayh/Dole; Issues related to oncology; Issues related to ophthalmology.
Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2024 · second_quarter · Q2
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues impacting rare disease treatments, including rare disease research incentives and the Creating Hope Reauthorization Act of 2024, H.R. 7384.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Issues related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to FY2024 appropriations.
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; issues related to drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues relating to Domestic API production.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELFI DIAGNOSTICS via TIBER CREEK GROUP
2024 · first_quarter · 1T
Issues related to cancer screenings.
Filing targets: SENATE
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328).
Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORMEDIX, INC. via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to infectious disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to IP protections under Bayh/Dole.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DAIICHI SANKYO, INC. via TIBER CREEK GROUP
2024 · first_quarter · RR
Issues related to implementation of drug pricing and reimbursement of prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; Issues related to IP protections under Bayh/Dole.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues impacting rare disease treatments, including rare disease research incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; issues related to drug pricing.
Issues related to FY2024 appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to HIV.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELFI DIAGNOSTICS via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to cancer screenings.
Filing targets: SENATE
CORMEDIX, INC. via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to infectious disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2023 · fourth_quarter · Q4
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 5378 - Lower Costs, More Transparency Act; S.2333 - Pandemics and All-hazards Preparedness and Response Act (PAHPARA); Issues related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to coverage decisions in FEP.
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issues related to Medicaid Rebates.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; H.R.5547/S.476 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANON, LLC via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169); Issues related to women's health; issues related to drug pricing.
Issues related to FY2024 appropriations.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169). Issues related to HIV.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEONE MEDICINES USA, INC. (FKA BEIGENE USA, INC.) via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to drug pricing and reimbursement for prescription drugs related to Inflation Reduction Act of 2022 (PL 117-169), Subtitle B (Part B and D drug pricing).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to FDA, Consolidated Appropriations Act, 2023 (PL 117-328).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). Issues related to women's health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 5378 - Lower Costs, More Transparency Act; S.2333 - Pandemics and All-hazards Preparedness and Response Act (PAHPARA); Issues related to drug shortages.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGACY COMMUNITY HEALTH SERVICES via TIBER CREEK GROUP
2023 · third_quarter · 3T
Implementation of American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; Issues related to implementation of Inflation Reduction Act of 2022 (PL 117-169).
Implementation of American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; Issues related to implementation of Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ACADIA PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues impacting rare disease treatments, including rare disease research incentives.
Issues related to drug pricing reforms; Implementation of the Inflation Reduction Act of 2022 (PL 117-169). Issues related to nursing home quality measures.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAKEDA PHARMACEUTICALS AMERICA, INC. via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via TIBER CREEK GROUP
2023 · third_quarter · Q3
H.R. 5388/S. 2740 - PREPARE Act of 2021, issues relating to Domestic API production.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DELFI DIAGNOSTICS via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to cancer screenings.
Filing targets: SENATE
CORMEDIX, INC. via TIBER CREEK GROUP
2023 · third_quarter · Q3
Issues related to infectious disease.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via TIBER CREEK GROUP
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LEGACY COMMUNITY HEALTH SERVICES via TIBER CREEK GROUP
2023 · second_quarter · Q2
Implementation of American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; Issues related to implementation of Inflation Reduction Act of 2022 (PL 117-169).
Implementation of American Rescue Plan Act of 2021 (PL 117-2); Issues related to COVID recovery; Issues related to implementation of Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR CLINICAL ONCOLOGY via TIBER CREEK GROUP
2023 · second_quarter · Q2
Issues related to research funding.
Issues related to oncology care, physician reimbursement, and the cost of prescription drugs; Implementation of Inflation Reduction Act of 2022 (PL 117-169); H.R. 8487/S. 3018 - Improving Seniors' Timely Access to Care Act; H.R. 830/S. 1375 - Help Ensure Lower Patient Copays Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via TIBER CREEK GROUP
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Fish & Wildlife Service (USFWS)
SIEMENS HEALTHINEERS via TIBER CREEK GROUP
2023 · second_quarter · Q2
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via TIBER CREEK GROUP
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B Pricing Reform; Issue relating to Home infusion under Medicare FFS; S.476 - Maintaining Investments in New Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE